Honey and Nigella Sativa in COVID-19 Prophylaxis

Sohaib Ashraf1,000 enrolled

Overview

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

1,000

Conditions

Covid19

Interventions

HoneyDRUG

0.5 gm/Kg/day honey

Nigella sativa seedDRUG

40 mg/Kg/day

PlaceboOTHER

empty capsule with sugar water

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Health care professionals Post-exposure COVID-19 Exclusion Criteria: * Multi-organ failure active COVID-19

Locations (1)

Shaikh Zayed Post-Graduate Medical Institute

Lahore, MA, Pakistan

RECRUITING

Outcomes

Primary Outcomes

SARS-CoV-2 infection rate

RT-PCR SARS-CoV-2

Time frame: 14 days

Central Contacts

Sohaib Ashraf, MBBS

CONTACT

8573167995 sohaib@skzmdc.edu.pk

Ahmad Imran, MBBS

CONTACT

+923338110708 ahmad.imran@skzmdc.edu.pk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.